Current Document Type: HighlightsVideoPage AML: Early Findings on Quizartinib and Milademetan - JADPRO

Watch More Highlights

Lindsey M. Lyle, MS, PA-C, of the University of Colorado Cancer Center, discusses preclinical study findings on synergistic antileukemic activity with a combination of the FLT3 inhibitor quizartinib and the MDM2 inhibitor milademetan in FLT3-ITD–mutant/p53 wild-type acute myeloid leukemia models (Abstract 2720).

Copyright © 2010-2022 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.